Treatment with Krestin combined with mitomycin C, and effect on immune response.
The combination effects of Krestin (PSK) and mitomycin C (MMC) were examined in experimental tumor models. PSK was administered either orally or intraperitoneally. Delayed-type footpad reaction and antibody formation against sheep erythrocytes were measured in hosts of which immune functions were depressed by tumor burden. Results of the experiment indicated that the simultaneous administration of PSK and MMC significantly increased the survival rate of tumor-bearing mice and restored more effectively their immune functions compared to those of nontreated tumor-bearing controls or tumor-bearing hosts treated with a single agent.
Fujii
T
T
Biomedical Research Laboratories, Kureha Chemical Industrie Co., Ltd., Tokyo, Japan.
Sugita
N
N
Kobayashi
Y
Y
Saito
K
K
Iijima
H
H
Matsunaga
K
K
Ando
T
T
Oguchi
Y
Y
Morita
I
I
Yoshikumi
C
C
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006968:Hypersensitivity, Delayed; D051379:Mice; D008809:Mice, Inbred C3H; D008813:Mice, Inbred ICR; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology; D011509:Proteoglycans / Q000008:administration & dosage*
D008937:Mitomycins; D011509:Proteoglycans; C010770:polysaccharide-K; D016685:Mitomycin